• News
  • SAN DIEGO
  • BioTech

FDA accepts NDA submission for carbamazepine IV

Ligand Pharmaceuticals Inc.'s Captisol licensee Lundbeck LLC announced that the FDA has accepted for review a new drug application for its investigational therapy intravenous carbamazepine.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11085 N. Torrey Pines Rd. Ste., 300
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
89.67
  0.44  
+ 0.49%
211,899,000
90.48
41.99

Insider Trade Data

Date Insider Shares Type Value
05/20/2015 Aryeh, Jason M 9,240 Sell $807,047
05/14/2015 De Silva, Nishan M 68,363 Sell $5,736,516
05/14/2015 De Silva, Nishan M 68,363 Exchange $2,404,278
05/14/2015 De Silva, Nishan M 68,363 Sell $5,736,516
05/14/2015 De Silva, Nishan M 68,363 Exchange $2,404,278

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology
Subscribe Today!